Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized trial of atacicept in IgA nephropathy
jRCT2080223899Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of atacicept in IgA nephropathy (IgAN) (7 arms), sponsored by Merck KGaA. Started May 2018; status: completed.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2080223899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223899.